EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction
- PMID: 25613154
- DOI: 10.1016/j.eururo.2014.12.038
EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction
Abstract
Context: Lower urinary tract symptoms (LUTS) represent one of the most common clinical complaints in adult men and have multifactorial aetiology.
Objective: To develop European Association of Urology (EAU) guidelines on the assessment of men with non-neurogenic LUTS.
Evidence acquisition: A structured literature search on the assessment of non-neurogenic male LUTS was conducted. Articles with the highest available level of evidence were selected. The Delphi technique consensus approach was used to develop the recommendations.
Evidence synthesis: As a routine part of the initial assessment of male LUTS, a medical history must be taken, a validated symptom score questionnaire with quality-of-life question(s) should be completed, a physical examination including digital rectal examination should be performed, urinalysis must be ordered, post-void residual urine (PVR) should be measured, and uroflowmetry may be performed. Micturition frequency-volume charts or bladder diaries should be used to assess male LUTS with a prominent storage component or nocturia. Prostate-specific antigen (PSA) should be measured only if a diagnosis of prostate cancer will change the management or if PSA can assist in decision-making for patients at risk of symptom progression and complications. Renal function must be assessed if renal impairment is suspected from the history and clinical examination, if the patient has hydronephrosis, or when considering surgical treatment for male LUTS. Uroflowmetry should be performed before any treatment. Imaging of the upper urinary tract in men with LUTS should be performed in patients with large PVR, haematuria, or a history of urolithiasis. Imaging of the prostate should be performed if this assists in choosing the appropriate drug and when considering surgical treatment. Urethrocystoscopy should only be performed in men with LUTS to exclude suspected bladder or urethral pathology and/or before minimally invasive/surgical therapies if the findings may change treatment. Pressure-flow studies should be performed only in individual patients for specific indications before surgery or when evaluation of the pathophysiology underlying LUTS is warranted.
Conclusions: These guidelines provide evidence-based practical guidance for assessment of non-neurogenic male LUTS. An extended version is available online (www.uroweb.org/guidelines).
Patient summary: This article presents a short version of European Association of Urology guidelines for non-neurogenic male lower urinary tract symptoms (LUTS). The recommended tests should be able to distinguish between uncomplicated male LUTS and possible differential diagnoses and to evaluate baseline parameters for treatment. The guidelines also define the clinical profile of patients to provide the best evidence-based care. An algorithm was developed to guide physicians in using appropriate diagnostic tests.
Keywords: Benign prostatic hyperplasia; Bladder outlet obstruction; Clinical practice guidelines; Detrusor overactivity; Diagnosis; Lower urinary tract symptoms; Nocturia; Nocturnal polyuria; Overactive bladder.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Re: Christian Gratzke, Alexander Bachmann, Aurelien Descazeaud, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur Urol 2015;67:1099-109.Eur Urol. 2015 Jul;68(1):e15. doi: 10.1016/j.eururo.2015.02.031. Epub 2015 Mar 11. Eur Urol. 2015. PMID: 25770488 No abstract available.
-
Lower urinary tract symptoms in men: refocus on your patients.Eur Urol. 2015 Jun;67(6):1110-1111. doi: 10.1016/j.eururo.2015.03.035. Epub 2015 Mar 31. Eur Urol. 2015. PMID: 25840623 No abstract available.
-
Re: EAU Guidelines on the Assessment of Non-Neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction.J Urol. 2016 Dec;196(6):1712-1714. doi: 10.1016/j.juro.2016.09.017. Epub 2016 Sep 14. J Urol. 2016. PMID: 27845123 No abstract available.
Similar articles
-
Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.Eur Urol. 2023 Aug;84(2):207-222. doi: 10.1016/j.eururo.2023.04.008. Epub 2023 May 17. Eur Urol. 2023. PMID: 37202311 Review.
-
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13. Eur Urol. 2013. PMID: 23541338 Review.
-
[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. Prog Urol. 2012. PMID: 23178093 French.
-
[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2. Prog Urol. 2015. PMID: 25841758 French.
-
Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.Health Technol Assess. 2020 Sep;24(42):1-122. doi: 10.3310/hta24420. Health Technol Assess. 2020. PMID: 32902375 Free PMC article. Clinical Trial.
Cited by
-
Clinical outcome and safety of holmium laser prostate enucleation after transrectal prostate biopsies for benign prostatic hyperplasia.Investig Clin Urol. 2024 Mar;65(2):148-156. doi: 10.4111/icu.20230276. Investig Clin Urol. 2024. PMID: 38454824 Free PMC article.
-
Single-cell transcriptomics reveal the remodeling landscape of bladder in patients with obstruction-induced detrusor underactivity.MedComm (2020). 2024 Feb 26;5(3):e490. doi: 10.1002/mco2.490. eCollection 2024 Mar. MedComm (2020). 2024. PMID: 38414668 Free PMC article.
-
Patient reported outcome and quality of life measured by a simple questionnaire in patients with symptomatic benign prostate hyperplasia treated by holmium laser enucleation of the prostate (HoLEP).Front Surg. 2024 Feb 8;11:1358701. doi: 10.3389/fsurg.2024.1358701. eCollection 2024. Front Surg. 2024. PMID: 38389860 Free PMC article.
-
Defining minimal invasive surgical therapy for benign prostatic obstruction surgery: Perspectives from a global knowledge, attitude, and practice survey.Asian J Urol. 2024 Jan;11(1):55-64. doi: 10.1016/j.ajur.2022.02.011. Epub 2022 Aug 17. Asian J Urol. 2024. PMID: 38312819 Free PMC article.
-
Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes.World J Urol. 2024 Feb 3;42(1):70. doi: 10.1007/s00345-023-04735-y. World J Urol. 2024. PMID: 38308714 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
